š”š²šš š¦ššŗšŗš®šæš
ā¢ Lupin reported a stellar set of earnings for the July-September quarter, with a surge in net profit and strong revenue growth driven by the launch of blockbuster respiratory drug Spiriva in the US market.
ā¢ The company's operational performance also improved dramatically, with the EBITDA margin expanding 800 basis points on year to 19.4 percent.
ā¢ The India market underperformed, growing just 7 percent due to weaker acute sales, but the company's strong performance in other markets more than made up for it.